Ivonescimab frente al pembrolizumab en el NSCLC positivo para PD-L1

Mingyang Xue1, Wenyi Jin2

  • 1Department of Orthopaedics, Renmin Hospital of Wuhan University, Wuhan University, Wuhan 430064, China; School of Medicine, Kunming University of Science and Technology, Kunming, China.

Lancet (London, England)
|September 27, 2025
PubMed
Resumen

No abstract available in PubMed .